Inhibition of insulin‑like growth factor 1 signaling synergistically enhances the tumor suppressive role of triptolide in triple‑negative breast cancer cells

  • Authors:
    • Hongyan Wu
    • Ting Sun
    • Rui Bi
  • View Affiliations

  • Published online on: May 14, 2019     https://doi.org/10.3892/ol.2019.10356
  • Pages: 822-829
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Triptolide (TPL) is an active extract from a Chinese herb, which has been used for centuries in China. TPL exhibits numerous bioactivities and pharmacological effects, including antitumor, anti‑inflammatory and immunosuppressive activities. However, previous studies have further revealed a multi‑target toxicity of TPL, including reproductive toxicity, hepatotoxicity and renal cytotoxicity. To validate the clinical benefit and reduce the risk of TPL application, studies have investigated the combination of TPL with other reagents to allow lower doses and decrease toxicity. The present study reported that TPL and the insulin‑like growth factor‑1 receptor (IGF1R) inhibitor AG1024synergistically inhibited cell proliferation and induced apoptosis in triple‑negative breast cancer cells. Overexpression of B‑cell lymphoma 2 partially reversed the TPL and AG1024‑induced increase in apoptosis. A similar synergistic effect was observed with a combination of AG1024 and cisplatin, a DNA damage inducer, in MDA‑MB‑231 cells. These results suggested that inhibition of IGF1R may sensitize triple‑negative breast cancer cells to DNA damage inducers. Using publicly available data from The Cancer Genome Atlas, an amplification and gain of copy number of IGF1R was observed in 38% of triple‑negative breast tumors (n=82), 26% of estrogen receptor (ER)‑negative tumors (n=174) and 10% of ER‑positive tumors (n=594). Similarly, a higher alteration frequency of IGF1R was identified in basal‑like breast tumors compared with luminal A/B‑like breast tumors. Overexpressed proteins associated with these alterations were revealed to be significantly enriched in multiple oncogenic signaling pathways, key transcription factor networks and DNA repair pathways. In summary, the present study suggested that inhibition of IGFR signaling and induction of DNA damage may exhibit synergistic effects for the treatment of triple‑negative and ER‑negative breast cancer.
View Figures
View References

Related Articles

Journal Cover

July-2019
Volume 18 Issue 1

Print ISSN: 1792-1074
Online ISSN:1792-1082

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Wu H, Sun T and Bi R: Inhibition of insulin‑like growth factor 1 signaling synergistically enhances the tumor suppressive role of triptolide in triple‑negative breast cancer cells. Oncol Lett 18: 822-829, 2019.
APA
Wu, H., Sun, T., & Bi, R. (2019). Inhibition of insulin‑like growth factor 1 signaling synergistically enhances the tumor suppressive role of triptolide in triple‑negative breast cancer cells. Oncology Letters, 18, 822-829. https://doi.org/10.3892/ol.2019.10356
MLA
Wu, H., Sun, T., Bi, R."Inhibition of insulin‑like growth factor 1 signaling synergistically enhances the tumor suppressive role of triptolide in triple‑negative breast cancer cells". Oncology Letters 18.1 (2019): 822-829.
Chicago
Wu, H., Sun, T., Bi, R."Inhibition of insulin‑like growth factor 1 signaling synergistically enhances the tumor suppressive role of triptolide in triple‑negative breast cancer cells". Oncology Letters 18, no. 1 (2019): 822-829. https://doi.org/10.3892/ol.2019.10356